FI924551A - Farmaceutiska foereningar - Google Patents

Farmaceutiska foereningar Download PDF

Info

Publication number
FI924551A
FI924551A FI924551A FI924551A FI924551A FI 924551 A FI924551 A FI 924551A FI 924551 A FI924551 A FI 924551A FI 924551 A FI924551 A FI 924551A FI 924551 A FI924551 A FI 924551A
Authority
FI
Finland
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
carboxy
Prior art date
Application number
FI924551A
Other languages
English (en)
Other versions
FI924551A0 (fi
Inventor
Colin Peter Dell
Colin William Smith
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI924551A0 publication Critical patent/FI924551A0/fi
Publication of FI924551A publication Critical patent/FI924551A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
FI924551A 1991-10-09 1992-10-08 Farmaceutiska foereningar FI924551A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
FI924551A0 FI924551A0 (fi) 1992-10-08
FI924551A true FI924551A (fi) 1993-04-10

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924551A FI924551A (fi) 1991-10-09 1992-10-08 Farmaceutiska foereningar

Country Status (22)

Country Link
US (1) US5284868A (fi)
EP (1) EP0537949B1 (fi)
JP (1) JPH05194477A (fi)
KR (1) KR100228841B1 (fi)
CN (1) CN1034938C (fi)
AT (1) ATE167859T1 (fi)
AU (1) AU658003B2 (fi)
CA (1) CA2079428A1 (fi)
CZ (1) CZ281688B6 (fi)
DE (1) DE69226060T2 (fi)
DK (1) DK0537949T3 (fi)
ES (1) ES2117035T3 (fi)
FI (1) FI924551A (fi)
HU (1) HU218916B (fi)
IL (1) IL103356A (fi)
MX (1) MX9205714A (fi)
MY (1) MY111368A (fi)
NO (1) NO301587B1 (fi)
NZ (1) NZ244627A (fi)
PH (1) PH30659A (fi)
RU (1) RU2071472C1 (fi)
TW (1) TW221292B (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP0599514A3 (en) * 1992-11-18 1994-07-06 Lilly Industries Ltd Pyranoquinoline derivatives as inhibitors of cell proliferation.
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
AU781986B2 (en) * 1999-11-05 2005-06-23 Cytovia, Inc. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092076A1 (en) 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
ATE450531T1 (de) * 2001-05-16 2009-12-15 Cytovia Inc Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003097806A2 (en) * 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7476741B2 (en) * 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
EP1789079B1 (en) * 2004-09-09 2012-11-07 Howard Florey Institute Of Experimental Physiology And Medicine Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
CA2770430A1 (en) * 2005-02-16 2006-08-24 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
NZ585338A (en) * 2007-11-19 2012-08-31 Howard Florey Inst Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
CN107235954A (zh) 2010-11-12 2017-10-10 德国癌症研究中心 作为Wnt通路拮抗剂的色烯衍生物及其类似物
CN104185631A (zh) * 2011-11-10 2014-12-03 纪念斯隆-凯特琳癌症中心 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (ru) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Способ получени 2-ароил-3н- нафто 2,1-в пиранонов-3
EP0412160A4 (en) * 1988-04-14 1991-09-11 Yamanouchi Pharmaceutical Co. Ltd. Substance q-2819 and process for its preparation

Also Published As

Publication number Publication date
CZ281688B6 (cs) 1996-12-11
AU658003B2 (en) 1995-03-30
AU2621692A (en) 1993-04-22
JPH05194477A (ja) 1993-08-03
DK0537949T3 (da) 1999-02-15
NO923910D0 (no) 1992-10-08
NZ244627A (en) 1994-12-22
ATE167859T1 (de) 1998-07-15
ES2117035T3 (es) 1998-08-01
HU9203183D0 (en) 1992-12-28
RU2071472C1 (ru) 1997-01-10
CN1034938C (zh) 1997-05-21
PH30659A (en) 1997-09-16
NO301587B1 (no) 1997-11-17
US5284868A (en) 1994-02-08
DE69226060T2 (de) 1998-11-19
TW221292B (fi) 1994-02-21
MX9205714A (es) 1993-04-01
KR100228841B1 (ko) 1999-11-01
CA2079428A1 (en) 1993-04-10
IL103356A0 (en) 1993-03-15
HUT62281A (en) 1993-04-28
DE69226060D1 (de) 1998-08-06
HU218916B (hu) 2000-12-28
EP0537949A1 (en) 1993-04-21
FI924551A0 (fi) 1992-10-08
IL103356A (en) 1998-02-22
MY111368A (en) 1999-12-31
EP0537949B1 (en) 1998-07-01
NO923910L (no) 1993-04-13
CN1073437A (zh) 1993-06-23
CZ303592A3 (en) 1993-12-15
KR930007931A (ko) 1993-05-20

Similar Documents

Publication Publication Date Title
FI924551A0 (fi) Farmaceutiska foereningar
CO5150224A1 (es) Compuestos de triazol y su utilizacion
TW568896B (en) Calcium receptor-active compounds
FI913782A (fi) Isoxazolderivat.
NO983099L (no) Nye retrovirale proteasehemmere
FI951731A0 (fi) Heterosykliset yhdisteet, joilla on sokeritautia vastustava vaikutus, niiden valmistus ja käyttö
DK0769010T3 (da) 2-[1',2',4'-triazol-3'-yloxymethylen]-anilider og deres anvendelse som pesticider
DK0641325T3 (da) Inhibitorer af retroviral protease
FI930977A0 (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
ATE261960T1 (de) Sulfonamide mit elastase inhibierender wirkung
MY109777A (en) Pharmaceutical compounds therewith
DK0743938T3 (da) Substituerede spiroforbindelser til behandling af inflammation
DK0639173T3 (da) Visse 2- (2'-methyl-3', 4'-trisubstitueret benzoyl) -1,3-cyklohexandioner
FI911138A0 (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
CO4950554A1 (es) Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida
FI904449A0 (fi) N-azasicyklo/3.3.0/oktanamider av aromatiska syror.
ID24231A (id) Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis
ES8303438A1 (es) Un procedimiento para la preparacion de perfluoroamidas
MX9204939A (es) Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
TH17774A (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้
TH17774EX (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้
IT1162465B (it) Procedimento per proteggere materiali cheratinici da insetti ed agenti nonche' composti barbiturici per esso
CO5210866A1 (es) Inhibidores de cinasas, de pirrolotriazina
TH6968A (th) ไตรสับสทิทิวด์ 1,3,5-ไตรเอซีน 2,4,6-ไตรโอน